http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Abbott, the U.S. Department of Defense and TRACK-TBI Partner to Study Point-of-Care Blood Test for Concussions
-
Absolute to Participate in Two May Conferences: the Jefferies 2019 Software Conference and the 4th Annual Oppenheimer Emerging Growth Conference
-
New Study Finds Abbott Blood Test Can Help Predict Future Cardiac Events in Adults with No Known Heart Disease
-
Absolute to Host Conference Call for Fiscal 2019 Third Quarter Financial Results
-
Absolute Declares Quarterly Dividend
-
New Absolute Research Reveals That Endpoint Security Tools Fail, Reliably and Predictably
-
Abbott Reports First-Quarter 2019 Results
-
Abbott and the Abbott Fund Support Relief Efforts for Cyclone Idai
-
Abbott Hosts Conference Call for First-Quarter Earnings
-
Abbott (ABT) Announces CE Mark for Alinity m Diagnostics System and Assays
-
Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients
-
New Data for Abbott's HeartMate 3™ Highlights Unparalleled Performance of Industry's Leading Heart Pump
-
New Late-Breaking Analyses from Landmark COAPT™ Trial Show Benefits of Abbott's MitraClip™ Device
-
Abbott Receives FDA Approval for Expanded Indication for MitraClip™ Device
-
Abbott (ABT) Says Late-Breaking Data Presentations at ACC Highlight its Leading Cardiovascular Portfolio
-
Late-Breaking Data Presentations at ACC 2019 Highlight Abbott's Leading Cardiovascular Portfolio
-
Abbott's Latest Diagnostics Technology, Alinity, Selected by Regional Medical Laboratory, Inc. to Deliver Benefits to Hospitals and Patients
-
Absolute Appoints Distinguished Security Expert and Technologist Dr. Nicko van Someren as Chief Technology Officer
-
Absolute Named a Leader in 2019 G2 Crowd Report on Endpoint Management Software
-
Abbott to Present at Barclays Global Healthcare Conference
-
Abbott Declares 381st Consecutive Quarterly Dividend
-
Absolute Selected as a Top Employer in British Columbia for 2019
-
New Real-World Evidence Analysis of Nearly Half a Million FreeStyle® Libre System Users Shows Higher Rates of Scanning Improves Glucose Control
-
Absolute to Present at the 15th Annual AGC Partners’ Information Security & Broader Technology Growth Conference
-
Abbott and Novo Nordisk Enter Partnership to Provide Integrated Digital Solution to People with Diabetes Using Insulin
-
Abbott Introduces the World's Most Sensitive Rapid Diagnostic Test, Determine™ HBsAg 2, to Accelerate Hepatitis B Care
-
Abbott Reports 2018 Results and Issues Strong Forecast for 2019
-
Abbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation
-
Japanese Red Cross Society Selects Abbott Technology to Screen Country's Blood and Plasma Supply
-
Abbott (ABT) to Acquire Cephea Valve Technologies
-
Abbott To Acquire Cephea Valve Technologies, Inc.
-
Abbott (ABT) Announces FDA Approval of World's First Device for Treatment of Premature Babies and Newborns with Opening in Their Hearts
-
FDA Approves World's First Device for Treatment of Premature Babies and Newborns with an Opening in Their Hearts (a Common Congenital Defect)
-
Abbott and "Malaria No More" Work Together to End Malaria in Odisha, India
-
Get Bubbly this New Year with Abbott's New Pedialyte® Sparkling Rush™ Powder Packs
-
Abbott Hosts Conference Call for Fourth-Quarter Earnings
-
Abbott Raises Quarterly Dividend 14%, Increasing Payouts for 47 Straight Years
-
Absolute Reports Voting Results of Election of Directors
-
Abbott to Present at J.P. Morgan Healthcare Conference
-
New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant
-
Abbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC
-
Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results
-
Abbott (ABT) Says HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for Heart Transplant
-
Abbott's HeartMate 3 Heart Pump Now FDA Approved for Advanced Heart Failure Patients Not Eligible for a Heart Transplant
-
Abbott's (ABT) Novel Diagnostic Test Shows Potential for Rapid Point-of-Care Cardiac Evaluations in New Data Published Online
-
New Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care
-
Abbott Reports Third-Quarter 2018 Results
-
Abbott (ABT) Names Robert B. Ford President COO
-
Abbott Names Robert B. Ford President, Chief Operating Officer
-
Abbott's (ABT) FreeStyle Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe

